Drugs / 4-1BB Selected Tumor Infiltrating Lymphocytes (TIL)
4-1BB Selected Tumor Infiltrating Lymphocytes (TIL)
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02111863 | Feb 2014 → Jul 2016 | melanoma, skin cancer | National Cancer Institute (NCI) | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 4-1BB Selected Tumor Infiltrating Lymphocytes (TIL) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02111863 ↗ |
| Route | Intravenous | “cells will be infused intravenously (i.v.)” NCT02111863 ↗ |